The aim of our study was to determine whether a low dose of 0.3125mg intravitreal bevacizumab is effective in treatment of type 1 ROP as the standard 0.625 mg dose., regarding : Serum Systemic VEGF levels. Retinal Vascularization.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
19
Serum systemic level of VEGF was measured before and after 1 week and 4 weeks of intravitreal injection of bevacizumab
Faculty of Medicine Cairo University
Cairo, Egypt
Change in the serum systemic VEGF pre- and post- intravitreal injection of bevacizumab in both groups.
serum systemic VEGF measured using human VEGF ELISA kit
Time frame: at day 0 (baseline ) , 1 week and 4 weeks post-injection
The number of infants without need for rescue therapy until 60 weeks of postmenstrual age after initial treatment.
Rescue therapy is defined as the need of a second dose of 0.625 mg bevacizumab reinjection or laser at any time during follow up period.
Time frame: "up to 60 weeks postmenstrual age"
Occurrence of any adverse events from intravitreal-injection
endophthalmitis , retinal detachment , cataract , vitreous hemorrhage
Time frame: Within 4 weeks from intravitreal injection
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.